Highlights of @ducky 's COVID-19 roundup https://covidbc.webfoot.com/2025/03/07/2025-03-07-general/ this week:
(2024-06-16)
(2024-06-16)
ten people out of 27 had significant improvements after a stellate ganglion block: [...](2025-03-03)
The other fifteen partially responded, and got another treatment — which meant that their data couldn’t honestly be used in this comparison [...]
The two who did not respond at all to treatment were two of the three people who only had smell/taste issues
https://www.autonomicneuroscience.com/article/S1566-0702(24)00049-3/fulltext
air pollution and genetics both raise the risk of severe COVID-19 outcomes.(2025-02-28)
For each interquartile range–rise in air-pollution concentrations, the risks of COVID-19 infection were 96% higher for PM2.5 and PM10, 97% for NO2, and 98% for NOx.
https://www.pnas.org/doi/10.1073/pnas.2421513122
Asthmatics who got Paxlovid for COVID-19 infections were 35% less likely to be hospitalized than ones who got molnupiravir#CovidIsNotOver #SARSCoV2 #COVID19 #COVID #LC #LongCOVID
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-025-03156-2
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study - Respiratory Research
Background Few studies evaluated the effectiveness of COVID-19 antivirals specifically in the asthma population This study assessed short- and long-term effects of nirmatrelvir/ritonavir versus molnupiravir in asthma population.BioMed Central
